Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × Ramucirumab × Clear all

Phase

Phase 2 38 Phase 1 12 Phase 3 11 Phase 1/2 4 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 Paclitaxel 6 Leucovorin 6 Granulocyte Colony-Stimulating Factor 6 Filgrastim 6 Etoposide 6 Drug Therapy 6 Cisplatin 6 Oxaliplatin 5 Nivolumab 5 Fluorouracil 5 Doxorubicin 5 Carboplatin 5 Bevacizumab 5 Sirolimus 4 Rituximab 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Melphalan 4 Immunoglobulin G 4 Gemcitabine 4 Docetaxel 4 Disulfides 4 Cytarabine 4 Capecitabine 4 pembrolizumab 3 gallium 68 PSMA-11 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡